title: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the therapeutic effectiveness of fluorouracil (5-FU), doxorubicin, and methyl lomustine (CCNU) (FAMe), 5-FU, doxorubicin, and cisplatin (FAP), and FAMe alternating with triazinate (TZT) when compared with a standard therapy of 5-FU alone in patients with advanced gastric cancer.
  
  
  METHODS
  Two hundred fifty-two eligible patients selected for study had proven locally unresectable and/or metastatic gastric adenocarcinoma. The majority had nonmeasureable disease. They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course. Survival was the primary study end point.
  
  
  RESULTS
  None of the three drug combinations showed a significant advantage over 5-FU alone in improved performance score, weight gain, or patient survival. Each of the three combinations was more toxic than 5-FU alone.
  
  
  CONCLUSIONS
  FAMe, FAP, or FAMe alternating with TZT cannot be recommended for the therapy of advanced gastric carcinoma. Therapy of this disease should remain an experimental endeavor. It would seem reasonable to prove the value of any new treatment approach by a randomized comparison to simple therapy with 5-FU alone.
authors.affiliation: Illinois Oncology Research Association Community Clinical Oncology Program, Peoria.
authors.forename: S A
authors.initials: SA
authors.lastname: Cullinan
authors.forename: C G
authors.initials: CG
authors.lastname: Moertel
authors.forename: H S
authors.initials: HS
authors.lastname: Wieand
authors.forename: M J
authors.initials: MJ
authors.lastname: O'Connell
authors.forename: M A
authors.initials: MA
authors.lastname: Poon
authors.forename: J E
authors.initials: JE
authors.lastname: Krook
authors.forename: J A
authors.initials: JA
authors.lastname: Mailliard
authors.forename: L K
authors.initials: LK
authors.lastname: Tschetter
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage
chemical_list: D014227:Triazines; D008130:Lomustine; D004317:Doxorubicin; C012071:triazinate; D002945:Cisplatin; D005472:Fluorouracil